This page contains a Flash digital edition of a book.
PREFERENCE.


NICORETTE NO.1 FOR


nicotine


*BASED ON SALES DATA. Nicorette®


Invisi Patch. Presentation: Transdermal patches releasing a nominal of 25mg, 15mg or 10mg of nicotine per


16 hours. Uses: Nicorette Invisi patch relieves and/or prevents cravings and nicotine withdrawal symptoms associated with tobacco dependence. It is indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. Nicorette Invisi patch is indicated in pregnant and lactating women making a quit attempt. Legal category: GSL. PL holder: McNeil Products Limited, Foundation Park, Roxborough way, Maidenhead, Berkshire, SL6 3UG, UK. Information about this product, including adverse reactions, precautions, contraindications, and method of use can be found at: http://www.mhra.gov. uk/spc-pil/?IdcService=SS_GET_PAGE&nodeId=%3C%25%3D+nodeId+%25%3E&searchFiled=nicorette+invisi&Su bmitSearch=Search#retainDisplay


References 1. Nicorette ROA Unit Share Data YOY 2. Nicorette Nielsen Unit Share Data YOY 3. Nicorette IMS Unit Share Data YOY 4. Cahill K et al, JAMA 2014; 311(2): 193-194.


UK/NI/16-6594a(1) Date of preparation: September 2016


®


1–3*


Nothing beats NICORETTE dual support4 ®


NICORETTE® QuickMist 1mg/spray Mouthspray. Presentation: Each 0.07ml contains 1mg nicotine corresponding


to 1mg nicotine/spray dose. Uses: QuickMist relieves and/or prevents cravings and nicotine withdrawal symptoms associated with tobacco dependence. It is indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and a safer alternative to smoking for smokers and those around them. Nicorette QuickMist is indicated in pregnant and lactating women making a quit attempt. Legal category: GSL PL holder: McNeil Products Limited, Foundation Park, Roxborough Way, Maidenhead, Berkshire SL6 3UG, UK. Information about this product, including adverse reactions, precautions, contraindications and method of use can be found at: http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1450415871116.pdf.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64